Neopharmed Gentili Expands European Footprint with ORLADEYO® Acquisition
Deal News | Jul 02, 2025 | White & Case
Global law firm White & Case LLP is advising Neopharmed Gentili, an Italian pharmaceutical company, in its acquisition of the European business of ORLADEYO (berotralstat) from BioCryst Pharmaceuticals. This strategic acquisition aims to bolster Neopharmed Gentili's presence in the rare diseases sector throughout Europe. The transaction, which is expected to close in October 2025, involves an upfront payment of US$250 million and potential additional payments up to US$14 million based on achieving commercial milestones. White & Case is providing comprehensive legal support across multiple areas including M&A, intellectual property, tax, antitrust, and regulatory advice, leveraging a diverse team of partners and associates across New York, Milan, London, and other key cities.
Sectors
- Pharmaceuticals
- Legal Services
- Finance
Geography
- Europe – Neopharmed Gentili is acquiring the European business of ORLADEYO, indicating a strong geographical focus within Europe.
- Italy – Neopharmed Gentili is an Italian pharmaceutical company, central to the transaction.
- USA – BioCryst Pharmaceuticals is an American company selling its European business operations.
Industry
- Pharmaceuticals – Neopharmed Gentili operates in the pharmaceutical industry, particularly focusing on therapeutic solutions for rare diseases.
- Legal Services – White & Case LLP, a law firm, is involved in providing legal advisory services for this transaction, indicating an intersection with the legal services industry.
- Finance – The transaction involves financial elements, including deal financing and valuation, relevant to the finance industry.
Financials
- US$250 million – Upfront payment for the acquisition of ORLADEYO's European business from BioCryst Pharmaceuticals.
- US$14 million – Potential additional consideration based on achieving commercial milestones.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Neopharmed Gentili | Buyer | Company | Italian pharmaceutical company expanding its presence in the European rare disease market. |
| BioCryst Pharmaceuticals | Seller | Company | US-based pharmaceutical company known for developing treatments for rare diseases. |
| White & Case LLP | Legal Advisor | Company | Global law firm advising on the legal aspects of Neopharmed Gentili's acquisition. |
| Del Bono Family | Controlling Entity | People | Family ownership group controlling Neopharmed Gentili alongside financial partners. |
| Ardian | Controlling Entity | Company | One of the financial partners controlling Neopharmed Gentili. |
| Renaissance Partners | Controlling Entity | Company | Financial partner with an investment stake in Neopharmed Gentili. |